medicationPrescription only (US)Approved by the FDA (Celexa) as an SSRI for major depressive disorderCarries a boxed warning about increased suicidal thinking in children, adolescents, and young adults, and a dose-dependent QT-prolongation warning limiting doses above 40 mg/day
CitalopramBenefits, Dosage & Interactions
Also known as: Celexa
Citalopram, commonly known by its brand name Celexa, is an antidepressant belonging to the class of selective serotonin reuptake inhibitors (SSRIs). It is primarily prescribed for the treatment of depression. It is typically taken in the morning. The reported plasma half-life is about 35 hours, which shapes dosing frequency.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 2 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
2 human randomized trials and regulatory approval on file.
Plasma half-life
~35 h
Typical timing
morning
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- STAR*D used citalopram flexibly titrated up to 60 mg/day for major depressive disorder; the creatine-augmentation trial paired citalopram (or another SSRI) at standard antidepressant doses[1][2]
Reported for Citalopram in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Citalopram entry is written from. Each number matches an inline marker above.
- [1]Sequenced treatment alternatives to relieve depression (STAR*D): rationale and designRush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA · Controlled Clinical Trials · 2004 · Peer-reviewed · PMID 15061154
- [2]A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorderLyoo IK, Yoon S, Kim TS, Hwang J, Kim JE, Won W · The American Journal of Psychiatry · 2012 · Peer-reviewed · PMID 22864465
How to track Citalopram doses
Tracking Citalopram well takes four fields and a habit. Here is what to record so the log is still useful in three months.
- 1
Add the dose and unit
Log Citalopram with its dose in mg so totals stay comparable over time — including days when you split the dose or skip it.
- 2
Set the time of day and food rule
Typical timing is morning. Reminders fire at that time and can export to your calendar.
- 3
Check it against the rest of the stack
Run Citalopram through the interaction checker against everything else in the routine — supplements, peptides, hormones and prescriptions — before it becomes a daily habit.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 35 h, effects and timing shifts show up over days rather than instantly. Review Citalopram alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg
- Time of day
- Taken / skipped / delayed
- Any side effects or notable changes
References & Evidence
Sources on this page that document Citalopram dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Citalopram?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Citalopram, commonly known by its brand name Celexa, is an antidepressant belonging to the class of selective serotonin reuptake inhibitors (SSRIs). It is primarily prescribed for the treatment of depression. SSRIs work by increasing the levels of serotonin, a neurotransmitter, in the brain. Serotonin is believed to play a key role in mood regulation, and imbalances are associated with depressive disorders. Citalopram was approved by the U.S. Food and Drug Administration (FDA) in 1998.
As a prescription medication, Citalopram is typically taken orally, usually once daily. The dosage is determined by a licensed clinician based on the individual's specific condition, response to treatment, and other medical factors. It is not suitable for self-medication and requires ongoing professional supervision.
The medication is available in tablet and oral solution forms. While generally effective for many individuals, it is important to understand its potential side effects, drug interactions, and contraindications before starting treatment. Individuals should not discontinue Citalopram abruptly without consulting their healthcare provider, as this can lead to withdrawal symptoms. (FDA label, MedlinePlus)
What does the research say about Citalopram?
Tap a section to expand.
Citalopram's primary mechanism of action involves selectively inhibiting the reuptake of serotonin in the brain. Neurotransmitters are chemical messengers that transmit signals between nerve cells (neurons). After a signal is sent, neurotransmitters are typically reabsorbed back into the transmitting neuron in a process called reuptake.
In the case of serotonin, Citalopram blocks the serotonin transporter protein (SERT), preventing the reabsorption of serotonin into the presynaptic neuron. This blockade leads to an increased concentration of serotonin in the synaptic cleft, the space between neurons. Enhanced serotonin levels in the synapse allow for greater and prolonged stimulation of postsynaptic serotonin receptors. This sustained serotonergic activity is thought to help regulate mood, emotion, and behavior, thereby alleviating symptoms of depression.
Citalopram has minimal affinity for other neurotransmitter reuptake systems (e.g., norepinephrine, dopamine) and various neurotransmitter receptors (e.g., muscarinic, histaminergic, adrenergic). This selectivity for serotonin reuptake is what defines it as an SSRI and contributes to its specific therapeutic effects and side effect profile compared to other classes of antidepressants. (DrugBank, FDA label)
Source for this section: Sources for How does Citalopram work?: Jumps to this entry in the sources and references list at the end of the page.
The primary benefit of Citalopram is the treatment of major depressive disorder (MDD). Clinical studies have consistently shown its efficacy in reducing depressive symptoms. Users may experience improvements in mood, decreased feelings of sadness, anhedonia (loss of pleasure), and hopelessness. Other benefits include a reduction in symptoms related to anxiety often co-occurring with depression, such as agitation and irritability. (FDA label)
Specific benefits observed in individuals taking Citalopram for depression typically include:
* **Improved Mood:** Many individuals report a lift in mood and a reduction in persistent feelings of sadness.
* **Increased Energy Levels:** Depression can lead to fatigue and low energy. Citalopram can help restore energy levels.
* **Better Sleep:** While some may experience initial sleep disturbances, improvements in sleep patterns are often noted as treatment progresses.
* **Enhanced Concentration:** Depression can impair focus and concentration, and Citalopram may help improve cognitive function.
* **Restored Interest in Activities:** Anhedonia, the inability to experience pleasure, is a core symptom of depression. Citalopram can help individuals regain interest in hobbies and daily activities.
* **Reduced Anxiety:** Many individuals with depression also experience anxiety. Citalopram's mechanism of action can help alleviate co-occurring anxiety symptoms.
It's important to note that the full therapeutic effects of Citalopram may not be immediately apparent and often take several weeks to manifest. Users should continue treatment as prescribed by their clinician, even if initial improvements are subtle. (MedlinePlus, Mayo Clinic)
Citalopram's efficacy in treating major depressive disorder is well-established through numerous clinical trials and post-marketing surveillance. The FDA approval of Citalopram was based on evidence from adequately controlled clinical studies demonstrating its superiority over placebo in adults with depression. (FDA label)
A review of SSRIs, including Citalopram, published by the Cochrane Library, generally supports their effectiveness for acute treatment of major depression in adults, particularly for more severe forms of depression. While individual responses can vary, the overall body of evidence indicates a significant positive impact compared to placebo. (Cochrane)
Studies have also explored its effectiveness in specific populations, such as older adults, where it has shown similar efficacy to other SSRIs. Research consistently highlights the importance of adherence to treatment and sufficient duration to achieve optimal outcomes. Long-term studies indicate that Citalopram can be effective in preventing relapse of depressive episodes. (PubChem, NIH ODS)
Comparative studies suggest that while different SSRIs may have slightly different side effect profiles, their overall efficacy in treating depression is generally comparable. The choice of SSRI often comes down to individual patient response, tolerability, and specific symptoms. (DrugBank)
Like all medications, Citalopram can cause side effects, although not everyone experiences them. Most side effects are mild to moderate and may diminish over time as the body adjusts to the medication. Common side effects often include:
* Nausea
* Dry mouth
* Insomnia or sleepiness
* Diarrhea
* Sweating
* Tremor
* Sexual dysfunction (e.g., decreased libido, difficulty achieving orgasm or ejaculation)
Less common but more serious side effects can occur and require medical attention immediately:
* **Serotonin Syndrome:** Symptoms may include agitation, hallucinations, rapid heartbeat, fever, overactive reflexes, nausea, vomiting, diarrhea, and uncoordinated movements. This is a potentially life-threatening condition.
* **QT Prolongation/Arrhythmia:** Citalopram can cause a dose-dependent prolongation of the QT interval on an electrocardiogram (ECG), which can lead to serious heart rhythm abnormalities (Torsade de Pointes). This risk is higher with higher doses and in individuals with pre-existing heart conditions.
* **Suicidal Thoughts or Behavior:** Especially in children, adolescents, and young adults (under 25) at the beginning of treatment or when the dose is changed.
* **Seizures:** Though rare.
* **Allergic Reactions:** Rash, itching, swelling, severe dizziness, trouble breathing.
* **Hyponatremia (low sodium levels):** Symptoms can include headache, confusion, weakness, and unsteadiness, which can be severe.
If you experience any severe or concerning side effects, contact your healthcare provider immediately. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Citalopram carries several important warnings that patients and healthcare providers should be aware of:
* **Risk of Suicidality:** Antidepressants, including Citalopram, increase the risk of suicidal thoughts and behavior in children, adolescents, and young adults (up to 24 years of age) compared to placebo. Close monitoring for clinical worsening, suicidality, or unusual changes in behavior is essential, especially during the initial phase of treatment or when the dose is adjusted. Families and caregivers should be advised of the need for close observation. (FDA label)
* **QT Prolongation and Torsade de Pointes:** Citalopram can cause dose-dependent QT interval prolongation and has been associated with cases of Torsade de Pointes, ventricular fibrillation, and sudden death. Doses above 40 mg/day are generally not recommended due to this risk. Patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, or recent acute myocardial infarction are at higher risk. ECG monitoring may be considered in at-risk patients. (FDA label, EMA SmPC)
* **Serotonin Syndrome:** The development of potentially life-threatening serotonin syndrome or neuroleptic malignant syndrome (NMS)-like reactions can occur with SSRIs, particularly with concomitant use of other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort) and drugs that impair serotonin metabolism (e.g., MAOIs). Symptoms include mental status changes, autonomic instability, neuromuscular abnormalities, and gastrointestinal symptoms. (FDA label)
* **Activation of Mania/Hypomania:** In individuals with bipolar disorder, Citalopram may precipitate a manic or hypomanic episode. It should be used with caution in patients with a history of mania.
* **Discontinuation Syndrome:** Abrupt discontinuation of Citalopram can lead to withdrawal symptoms, which may include dizziness, sensory disturbances (e.g., electric shock sensations), sleep disturbances, agitation, anxiety, nausea, and sweating. It is important to gradually reduce the dose under the supervision of a clinician. (Mayo Clinic)
* **Seizures:** Citalopram should be used with caution in patients with a history of seizure disorder.
* **Hyponatremia:** Low sodium levels can occur, particularly in elderly patients and those taking diuretics. (FDA label)
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Citalopram is contraindicated in certain situations due to the risk of serious adverse effects:
* **Concomitant Use with Monoamine Oxidase Inhibitors (MAOIs):** Citalopram is strictly contraindicated for use with MAOIs, or within 14 days of discontinuing an MAOI. Conversely, an MAOI should not be started within 14 days of discontinuing Citalopram. This combination significantly increases the risk of developing serotonin syndrome, which can be fatal. (FDA label, EMA SmPC)
* **Concomitant Use with Pimozide:** Citalopram is contraindicated with pimozide, an antipsychotic medication, due to the risk of prolonging the QT interval and precipitating ventricular arrhythmias. Even low doses of Citalopram can significantly increase pimozide levels. (FDA label)
* **Known Hypersensitivity:** Individuals with a known allergy or hypersensitivity to Citalopram or any of its inactive ingredients should not take this medication. (FDA label)
* **Congenital Long QT Syndrome:** Patients with a congenital long QT syndrome or other conditions that increase the risk of QT prolongation are generally advised against using Citalopram, especially at higher doses, due to the risk of life-threatening heart arrhythmias. (FDA label)
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Mixing Citalopram with certain other medications or substances can lead to dangerous interactions, some of which can be life-threatening:
* **Monoamine Oxidase Inhibitors (MAOIs):** (e.g., phenelzine, tranylcypromine, isocarboxazid, selegiline, linezolid, methylene blue IV). Concurrent use is contraindicated and can lead to severe, potentially fatal serotonin syndrome. A washout period of at least 14 days is required between stopping an MAOI and starting Citalopram, and vice versa. (FDA label)
* **Pimozide:** Concomitant use is contraindicated due to increased risk of QT prolongation and cardiac arrhythmias. (FDA label)
* **Other Serotonergic Drugs:** Co-administration with other medications that increase serotonin levels can lead to serotonin syndrome. These include: triptans (for migraines), other SSRIs, SNRIs (serotonin-norepinephrine reuptake inhibitors), tricyclic antidepressants (TCAs), fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John's Wort. Careful monitoring and dose adjustments are necessary if these combinations are unavoidable. (FDA label)
* **Drugs that Prolong the QT Interval:** Combining Citalopram with other medications known to prolong the QT interval (e.g., certain antiarrhythmics like quinidine, procainamide, amiodarone, sotalol; some antipsychotics like thioridazine; certain antibiotics like moxifloxacin) can significantly increase the risk of dangerous heart rhythm problems. (FDA label)
* **Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Aspirin, Warfarin, and other Anticoagulants/Antiplatelets:** Co-administration can increase the risk of bleeding, particularly gastrointestinal bleeding, due to Citalopram's effect on platelet function. (FDA label)
* **Alcohol:** While not a direct pharmacokinetic interaction, alcohol is a central nervous system depressant and can worsen the symptoms of depression and anxiety, as well as exacerbate Citalopram's potential sedating side effects. It is generally advised to avoid alcohol while on Citalopram. (MedlinePlus)
* **Grapefruit Juice:** Some sources suggest grapefruit juice may interact with Citalopram, potentially increasing its concentration in the body, although this interaction is generally considered minor for Citalopram compared to some other SSRIs or medications. It's best to consult with your clinician regarding specific dietary interactions. (NIH ODS)
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Citalopram is typically taken orally once per day. The optimal timing for administration can vary between individuals based on how they experience side effects.
* **Morning Dose:** Many individuals take Citalopram in the morning with or without food. This timing is often preferred to minimize potential sleep disturbances such as insomnia, which can be a side effect for some people.
* **Evening Dose:** If Citalopram causes drowsiness or sedation, taking it in the evening before bedtime might be beneficial to help with sleep and reduce the impact of sedation during waking hours.
Citalopram can be taken with or without food. However, taking it with food may help to reduce gastrointestinal side effects like nausea or an upset stomach. The user's specific dose and timing instructions must be set by a licensed clinician. It is crucial to take the medication at approximately the same time each day to maintain consistent levels in the body. If a dose is missed, it should generally be taken as soon as remembered unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped to avoid taking a double dose. (MedlinePlus, FDA label)
Source for this section: Sources for When should you take Citalopram?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Citalopram?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source pending | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source pending | Specific pairs are checked against a licensed source; confirm with your provider. |
| Phenelzine | Avoid | Compound pairConfidence: theoretical | Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.Source pending | Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine). |
| Tranylcypromine | Avoid | Compound pairConfidence: theoretical | Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.Source pending | Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine). |
| Selegiline | Avoid | Compound pairConfidence: theoretical | Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.Source pending | Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine). |
| Rasagiline | Avoid | Compound pairConfidence: theoretical | Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.Source pending | Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine). |
Frequently asked questions about Citalopram
Citalopram is a medication. It is also known as Celexa. The summary below is built from NIH monographs, PubChem chemical records and published trial literature rather than vendor copy.
Citalopram is commonly discussed in the context of the goals discussed on its profile page. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Citalopram, it is typically taken in the morning and its approximate half-life is 35 hours, which influences dosing frequency. Always follow the specific dose your clinician or the product label prescribes.
Citalopram carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
Interaction risk for Citalopram comes from the rest of the stack: other medications, prescription medicines, hormone therapy and peptides. Because Citalopram is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 35 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Citalopram with no sign-up.
There is no single answer for Citalopram plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Pairing Citalopram with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
With a plasma half-life near 35 hours, once-daily dosing is the usual pattern for Citalopram. It is typically taken in the morning. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
With a plasma half-life near 35 hours, a single missed dose of Citalopram usually has a smaller effect on overall exposure than an irregular pattern of missed doses does. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Citalopram the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Citalopram?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis(opens PubMed in a new tab)BMC Psychiatry · 2023 · PMID 38001423 · https://pubmed.ncbi.nlm.nih.gov/38001423/
- 2.Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial(opens PubMed in a new tab)JAMA · 2014 · PMID 24549548 · https://pubmed.ncbi.nlm.nih.gov/24549548/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 10150457(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/10150457
Verify at
Publisher search links for Citalopram. These are places to check the information — they are not citations, so they are not numbered.
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- European Medicines Agency(publisher search, opens in a new tab)European Medicines Agency · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Citalopram?
Plain-text summary, safe to quote verbatim:
Citalopram, commonly known by its brand name Celexa, is an antidepressant belonging to the class of selective serotonin reuptake inhibitors (SSRIs). It is primarily prescribed for the treatment of depression. It is typically taken in the morning. The reported plasma half-life is about 35 hours, which shapes dosing frequency.
Source: DoseRoutine — https://doseroutine.com/library/citalopram
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Citalopram — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/citalopram
What compounds are similar to Citalopram?
Others in the medication category or studied for the same goals.